Dr Daniel John Wenzl, MD in Muscle Shoals, AL - Ophthalmology

Dr Daniel John Wenzl, MD is a Ophthalmology physician based in Muscle Shoals, Alabama. Dr Daniel John Wenzl is licensed to practice in Alabama (license number 00012269) and his current practice location is 203 Avalon Avenue, Suite 200, Muscle Shoals, Alabama. He can be reached at his office (for appointments etc.) via phone at (256) 386-1110.

NPI number for Dr Daniel John Wenzl is 1912016163 and his current mailing address is 203 Avalon Avenue, Suite 200, Muscle Shoals, Alabama. He does not participate in medicare program and thus does not accept medicare assignments. His NPI Number is 1912016163.

Contact Information

	Dr Daniel John Wenzl, MD
	203 Avalon Avenue, Suite 200, Muscle Shoals, AL 35661-2855
	(256) 386-1110
	(256) 386-1114

Physician's Profile

Full Name	Dr Daniel John Wenzl
Gender	Male
Speciality	Ophthalmology
Location	203 Avalon Avenue, Muscle Shoals, Alabama
Accepts Medicare Assignments	Does not participate in Medicare Program. He may not accept medicare assignment.

NPI Data:

NPI Number: 1912016163
Provider Enumeration Date: 08/30/2006
Last Update Date: 12/23/2011

Medical Identifiers

Medical identifiers for Dr Daniel John Wenzl such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1912016163	NPI	-	NPPES
000014931	Medicaid	AL
0000060830	Other	PA	BLUE CROSS BLUE SHIELD
0051047	Other	TN	BLUE CROSS BLUE SHIELD

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
207W00000X	Ophthalmology	00012269 (Alabama)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Dr Daniel John Wenzl is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Dr Daniel John Wenzl, MD 203 Avalon Avenue, Suite 200, Muscle Shoals, AL 35661-2855 Ph: (256) 386-1110	Dr Daniel John Wenzl, MD 203 Avalon Avenue, Suite 200, Muscle Shoals, AL 35661-2855 Ph: (256) 386-1110

News Archive

Children's Hospital Colorado helps prove safety and efficacy of CF treatment in younger pediatric patients

Researchers at the Children's Hospital Colorado Breathing Institute, the largest pediatric cystic fibrosis (CF) clinical care center in the U.S., participated in the pivotal international multi-center Phase 3 clinical trial, sponsored by Vertex Pharmaceuticals Incorporated, leading to FDA approval of TRIKAFTA (elexacaftor/tezacaftor/ivacaftor), a highly effective CF treatment, for patients ages 6 through 11 who have at least one copy of the F508del mutation.

Concerns about embryo disposition - 500,000 frozen embryos currently in storage

Fertility patients who are done having children feel responsible for the stored, frozen embryos left over from their treatment, yet more than half are against implanting the embryos in anyone else, according to a new study by researchers at Duke University Medical Center.

Masimo Rad-57 Pulse CO-Oximeter helps detect CO poisoning on-the-scene

Masimo, the inventor of Pulse CO-Oximetry™ and Measure-Through Motion and Low Perfusion pulse oximetry, today announced that the U.S. Department of Homeland Security recently issued a Federal warning about the increased risk of carbon monoxide exposure during the winter season—urging heightened awareness and precaution for firefighters, who are at increased risk of duty-related CO danger. The life-threatening consequences of CO poisoning make immediate detection, helped by the noninvasive Masimo Rad-57 Pulse CO-Oximeter, a lifesaving necessity for fire and emergency operations.

Researchers use magnetic brain stimulation to alleviate anxiety

It is possible to unlearn fears. And this works even better when a specific region of the brain has previously been stimulated magnetically. This has been shown by researchers from the Würzburg University Hospital in a new study.

Rowan University, Bamboo Therapeutics partner to combat Canavan disease

Rowan University and Bamboo Therapeutics, Inc. have entered into an asset transfer agreement to commercialize a novel gene therapy for the treatment of Canavan disease. A rare but devastating neurological disease that tragically takes a child's life by age 10, Canavan disease is one of the most common and complex degenerative cerebral diseases in infants.

Dr Daniel John Wenzl, MD - Ophthalmology in Muscle Shoals, AL